©2018 by Mana Therapeutics.

email contact: crcruz@manatherapeutics.com

LEADERSHIP

Martin B. Silverstein, M.D.
President and Chief Executive Officer

Marty Silverstein, M.D. joined Mana Therapeutics in November 2018 as its President and CEO.  Marty was most recently EVP, Strategy for Gilead Sciences, a leading biotechnology company, where his responsibilities included Corporate Strategy and Planning, Commercial Planning Corporate Development, and Alliance Management. He was an integral part of Gilead’s acquisition of Kite Pharma. Immediately prior to Gilead, Marty was EVP and Chief Strategy Officer at Anthem, the second largest US health insurer. His responsibilities at Anthem included Corporate Strategy and Innovation, Corporate Development, and Enterprise Marketing. Prior to Anthem, Marty had been a Senior Partner and Managing Director at The Boston Consulting Group, where he was a founding member of its Health Care Practice and recognized for his role in establishing its pharmaceutical practice. While at BCG, he had Increasing roles of increasing responsibility including Global Leader of the Health Care practice.

 

Marty received his Medical Degree from Yale University, and his MBA from the Harvard Business School. He graduated summa cum laude from the University of Pennsylvania with a degree in economics. He completed his internal medicine residency at Boston's Beth Israel Hospital, a major teaching hospital of Harvard Medical School, and is board certified in Internal Medicine.